Medicure Inc (CVE:MPH) had its price objective dropped by stock analysts at Pi Financial from C$13.25 to C$12.40 in a research report issued on Thursday. The brokerage currently has a “buy” rating on the stock. Pi Financial’s target price would suggest a potential upside of 66.22% from the stock’s previous close.

Shares of Medicure (CVE MPH) traded down C$0.69 during trading on Thursday, hitting C$7.46. 40,198 shares of the stock were exchanged, compared to its average volume of 19,730. Medicure has a fifty-two week low of C$6.00 and a fifty-two week high of C$10.67.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at

About Medicure

Medicure Inc (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS).

Receive News & Ratings for Medicure Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.